Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
Over 1,000 cancer treatment protocols
Medical Oncology, Hematology, Bone Marrow Transplantation
With administration details, lab parameters, indications, and summarized references
Updated monthly to include latest approvals and major papers
Reviewed by Medical Oncologists and Hematologists
New Indication: Avelumab for MSI-High Metastatic Colorectal Cancer
A Phase II, Randomized, Open-label, multicenter trial Progression under first-line treatment (except for immunotherapy) of dMMR/MSI metastatic colorectal cancer Avelumab (n=65) vs
New Reference: SubQ Rituximab for Follicular Lymphoma
Randomized, open-label phase 3 trial (LYSA) Previously untreated low-burden Follicular lymphoma SOC (n=102) vs. Rituximab sc (n=100)
New Reference: Ibrutinib and Rituximab for CLL
Phase III, randomized,controlled, multicenter, open-label trial (FLAIR) Treatment naive CLL–small lymphocytic lymphoma (SLL) İbrutinib + Rituximab (n=386) vs. FCR (n=385)
New Drug: Ripretinib for Advanced GIST
Randomized, open-label, international, multicenter phase III study Advanced GIST who progressed on or were intolerant to first-line treatment with imatinib Ripretinib 150 mg (n = 2
New Protocol: Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer
Multicenter, open-label, phase 1/2 trial Cisplatin ineligible local advanced/metastatic urothelial carcinoma Enfortumab vedotin +pembrolizumab q21 (n=45)
New Protocl: Trifluridine-Tipiracil and Bevacizumab in Metastatic Colorectal Cancer
Phase III, randomized, open-label trial (SUNLIGHT) Adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer
New Protocol: Pembrolizumab with Chemotherapy in Advanced Endometrial Cancer
Phase III, randomized, double-blind, placebo-controlled Advanced-stage, metastatic, or recurrent endometrial cancer of any histologic subtype except for carcinosarcoma Pembrolizuma
New Drug: Elacestrant for ER+ Breast Cancer
International, multicenter, randomized, open-label, phase III (EMERALD) ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretre
New Protocol: Perioperative FLOT with Trastuzumab and Pertuzumab for her2-Positive Gastroesophageal Cancer
Multicenter, randomized phase II/III trial HER 2–positive, >= clinical tumor 2 or clinical nodal–positive resectable EGA Four pre and postoperative cycles of either FLOT alone
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.
